Suppr超能文献

载脂蛋白-D:一种用于高级别前列腺上皮内瘤变和前列腺癌的新型细胞标志物。

Apolipoprotein-D: a novel cellular marker for HGPIN and prostate cancer.

作者信息

Hall R E, Horsfall D J, Stahl J, Vivekanandan S, Ricciardelli C, Stapleton A M F, Scardino P T, Neufing P, Tilley Wayne D

机构信息

Department of Surgery, Flinders University and Flinders Medical Centre, Adelaide, South Australia.

出版信息

Prostate. 2004 Feb 1;58(2):103-8. doi: 10.1002/pros.10343.

Abstract

BACKGROUND

High grade prostatic intraepithelial neoplasia (HGPIN) is a putative pre-malignant lesion of the prostate. While apolipoprotein-D (Apo-D), an androgen-regulated hydrophobic transporter protein, is expressed in prostate tumors, its expression in HGPIN is unknown.

METHODS

Immunoreactivity for Apo-D and another androgen-regulated protein, prostate specific antigen (PSA), was investigated in 64 radical prostatectomy tissues by video image analysis.

RESULTS

Eighty two percent of prostatectomy specimens demonstrated moderate to strong Apo-D immunoreactivity in areas of HGPIN. In comparison, weak Apo-D immunoreactivity was observed in non-malignant areas in only 24% of specimens. The median (range) percentage cellular area of HGPIN immunopositive for Apo-D (9.7%, 0-42.9), and the cellular concentration of Apo-D (MIOD 3.1, 0-13.3), were intermediate between that of normal (area 0%, 0-53.5%, MIOD 0, 0-12.6) and early stage prostate cancer tissues (area 29.2%, 0-90.8%, MIOD 6.7, 0-28.1). This increase in Apo-D expression from non-malignant, through HGPIN to prostate cancer was statistically significant (P < 0.001), and contrasted with the decrease observed in PSA staining between adjacent areas of normal glands, HGPIN, and cancer (P = 0.026).

CONCLUSIONS

The presence of high levels of immunoreactive Apo-D in HGPIN and prostate cancer, but not in non-malignant epithelial cells, is consistent with HGPIN being an intermediate lesion in the transition to prostate cancer, and suggests that cellular Apo-D expression is a marker of malignant transformation of the prostate.

摘要

背景

高级别前列腺上皮内瘤变(HGPIN)被认为是前列腺的一种癌前病变。载脂蛋白-D(Apo-D)是一种受雄激素调节的疏水转运蛋白,在前列腺肿瘤中表达,但其在HGPIN中的表达情况尚不清楚。

方法

通过视频图像分析,研究了64例前列腺癌根治术组织中Apo-D和另一种受雄激素调节的蛋白前列腺特异性抗原(PSA)的免疫反应性。

结果

82%的前列腺癌根治术标本在HGPIN区域显示中度至强的Apo-D免疫反应性。相比之下,仅24%的标本在非恶性区域观察到弱的Apo-D免疫反应性。HGPIN中Apo-D免疫阳性的细胞面积中位数(范围)为9.7%(0-42.9%),Apo-D的细胞浓度(平均光密度3.1,0-13.3)介于正常组织(面积0%,0-53.5%,平均光密度0,0-12.6)和早期前列腺癌组织(面积29.2%,0-90.8%,平均光密度6.7,0-28.1)之间。从非恶性组织、HGPIN到前列腺癌,Apo-D表达的这种增加具有统计学意义(P<0.001),这与在正常腺体、HGPIN和癌的相邻区域之间观察到的PSA染色减少形成对比(P = 0.026)。

结论

HGPIN和前列腺癌中存在高水平的免疫反应性Apo-D,但在非恶性上皮细胞中不存在,这与HGPIN是向前列腺癌转变的中间病变一致,并表明细胞Apo-D表达是前列腺恶性转化的一个标志物。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验